Annexon, Inc., was incorporated under the laws of the State of Delaware on March 3, 2011. The company is a clinical-stage biopharmaceutical company developing novel therapies for classical complement-mediated diseases of the body, brain and eyes. 

Annexon

Annexon's Cash Burn: Assessing the Company's Financial Viability

Annexon shares surge 13.91% premarket as Jefferies reiterates strong buy rating and highlights M&A-driven complement inhibitor demand.

Annexon Shares Surge as Q4 Results and Drug Development Updates Exceed Expectations

Annexon shares surge 20.56% intraday as Q4 loss beats estimates and vonaprument trial data expected in late 2026.

Annexon shares surge 14.15% intraday as Q4 loss beats estimates, cash reserves extend runway to 2027, and phase III trial data for vonaprument expected in late 2026.

ANNX News